Sermorelin

Chemical identity

Sermorelin is residues 1–29 of human growth hormone-releasing hormone, amidated at the C-terminus. The native hormone is 44 residues; everything past position 29 proved dispensable for receptor activation, which is why the truncated form became the standard research and diagnostic reagent.

The sequence contains a methionine at position 27. Methionine oxidises to the sulfoxide readily on exposure to air, and oxidised sermorelin has reduced activity — making oxygen exclusion during handling a functional requirement rather than good practice.

Mechanism in research models

Sermorelin binds the GHRH receptor on pituitary somatotrophs, a class B GPCR coupled to Gs. Activation raises cAMP, activates protein kinase A and triggers release of stored growth hormone, alongside a slower transcriptional effect on GH synthesis.

Because it acts upstream at the pituitary rather than replacing the hormone itself, the resulting GH release remains subject to somatostatin negative feedback and retains a pulsatile character. That preserved physiology is the entire reason the compound is used as a probe: it tests whether the axis works, rather than bypassing it.

This also makes sermorelin a diagnostic tool. A failure to respond localises a defect to the pituitary rather than the hypothalamus — a distinction that no downstream measurement can make.

What the literature establishes

Sermorelin has a long clinical history as a diagnostic agent for growth hormone deficiency and, historically, as a therapeutic in paediatric endocrinology. The pharmacology is well characterised and the receptor interaction is not in dispute.

Plasma half-life is short — minutes rather than hours — because of rapid dipeptidyl peptidase-4 cleavage at the N-terminal Tyr-Ala bond. This is the single most important practical fact about the molecule, and it is why later GHRH analogues such as CJC-1295 were engineered specifically to resist that cleavage.

For comparative work, note that sermorelin and the ghrelin-receptor secretagogues act through entirely separate receptors. Studies treating them as interchangeable GH-releasing agents are comparing different pharmacology.

Handling, reconstitution and storage

The lyophilised acetate salt is typically held at −20 °C, sealed, desiccated and protected from light; confirm the validated condition and the salt form on the lot documentation. At 29 residues this is a comparatively large and fragile peptide; it is less forgiving of ambient excursions than the short sequences elsewhere on this site.

Reconstitute gently with sterile or bacteriostatic water. Avoid vortexing and avoid introducing air — both accelerate methionine oxidation and surface denaturation.

Use reconstituted solution promptly and keep single-use aliquots frozen. Sermorelin in solution has a genuinely short working life, and there is no visual cue when oxidation has occurred.

Analytical documentation

Look for RP-HPLC purity, an observed mass matching the amidated 29-mer, and acetate content. For a peptide of this length, ask what the main impurity peaks are — deletion sequences from incomplete coupling are common in long syntheses and can co-elute closely with the target.

Where the intended use is quantitative, request amino-acid analysis for net peptide content. Gravimetric labelling on a 3.3 kDa acetate-salt peptide carries meaningful error.

References and authoritative sources

Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.

1. PubChem compound record (US National Library of Medicine)
2. PubMed indexed literature
3. DrugBank entry
4. ClinicalTrials.gov registered studies
5. UniProt protein record

These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.